Werewolf Therapeutics rises on plans to explore strategic alternatives

Shares of biotech co Werewolf Therapeutics HOWL.O rise 7.3% to 71 cents in after-hours trading

Co says it will explore a full range of strategic alternatives to advance its drug development pipeline

Co says "measures may include, among other options, a sale of the company, a business combination or merger, a sale of assets, licensing or collaboration arrangements, or other strategic transactions"

Co says it does not have a defined timeline for the review

Co has engaged Piper Sandler & Co to serve as financial adviser

Stock rose 57.2% in 2025